Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular Degeneration
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate changes in preferential hyperacuity perimeter (PHP)
and fundus autofluorescence (FAF) in patients with neovascular age-related macular
degeneration receiving combination of ranibizumab (LucentisTM) and verteporfin (Visudyne®)
therapy